Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Acoramidis shows strong real-world and clinical benefits over tafamidis in ATTR-CM.

What the company is saying

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is highlighting new real-world and Phase 3 clinical data for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), presented at the 2026 Heart Failure Society of America meeting. The company frames acoramidis as the only selective small molecule, orally administered, near-complete (≥90%) transthyretin stabilizer, emphasizing its comparative effectiveness versus tafamidis and placebo. The announcement details statistically significant reductions in composite clinical endpoints, hospitalizations, and disease progression markers, supported by hazard ratios and p-values. Multiple subgroup analyses, including variant and female patients, are presented to reinforce the breadth of benefit. Safety data are disclosed, with adverse event rates and discontinuation rates compared to placebo. The tone is confident, with claims of reproducibility across independent data sources and regulatory approvals in the US, EU, Japan, Switzerland, UK, and Brazil. The company acknowledges the need for further research and longer follow-up, but positions acoramidis as a differentiated therapy with broad clinical impact.

What the data suggests

The real-world analysis included 910 acoramidis-treated and 1,774 tafamidis-treated ATTR-CM patients, showing an 18% lower risk for the composite endpoint of death, all-cause hospitalization, new-onset atrial fibrillation, or diuretic intensification with acoramidis (HR 0.82; 95% CI 0.73-0.93; p<0.01). Acoramidis reduced cardiovascular and heart failure hospitalizations by 27% each (HR 0.73; 95% CI 0.62-0.86 and 0.62-0.87; both p<0.001), and all-cause hospitalization by 25% (HR 0.75; 95% CI 0.64-0.88; p<0.001). Diuretic intensification was 17% lower (HR 0.83; 95% CI 0.71-0.95; p<0.01). Differences in death (HR 0.85; 95% CI 0.62-1.20) and new-onset atrial fibrillation (HR 0.88; 95% CI 0.68-1.13) favored acoramidis but were not statistically significant. In the ATTRibute-CM trial, survival at 30 months dropped from 86.7% (no CVH) to 68.4% (one CVH) and 47.7% (two or more CVH). Acoramidis halved the annualized frequency of cardiovascular-related hospitalizations through Month 30 versus placebo (50% reduction; p<0.0001) and previously showed a 42% reduction in recurrent CVH/ACM. In p.Val142Ile variant patients, acoramidis attenuated 30-month declines in KCCQ-OS by 23.3 points (p=0.005), EQ VAS by 25.8 points (p=0.003), and EQ-5D-5L index by 0.26 (p=0.018), with a 69% reduction in risk of all-cause mortality or first CVH. Safety data showed diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) for acoramidis vs placebo, with discontinuation rates of 9.3% (acoramidis) and 8.5% (placebo). The data are robust, with consistent findings across analyses and endpoints, but longer-term mortality effects remain to be confirmed.

Analysis

The announcement is largely factual and data-driven, presenting realised clinical and real-world evidence for acoramidis in ATTR-CM, including statistically significant reductions in key clinical endpoints versus tafamidis and placebo. The majority of claims are supported by numerical data (hazard ratios, p-values, subgroup analyses), and regulatory approvals in multiple jurisdictions are confirmed. Forward-looking statements are present but clearly separated as future research directions or ongoing analyses, not as overhyped projections. There is no evidence of exaggerated tone or narrative inflation; the language is proportionate to the disclosed results. No large capital outlay or long-dated, uncertain returns are discussed. The only minor inflation is the claim that acoramidis is the 'only' selective small molecule, orally administered, near-complete TTR stabilizer, which is asserted without comparative evidence. The absence of commercial or financial data is not a deficiency for a clinical update of an approved product.

Risk flags

• ●The follow-up duration is relatively short due to the recent approval of acoramidis, limiting the ability to assess long-term endpoints such as mortality and new-onset atrial fibrillation. This introduces uncertainty regarding the durability of observed benefits.
• ●As with all observational studies, residual confounding may persist despite propensity-score matching and sensitivity analyses. This could bias comparative effectiveness results in real-world settings.
• ●The small sample size in some subgroups, such as the p.Val142Ile variant and women, limits statistical power and precision, making subgroup findings less definitive.
• ●Adverse event rates for diarrhea (11.6%) and upper abdominal pain (5.5%) are higher with acoramidis than placebo, though most events were mild and did not lead to higher discontinuation rates.
• ●The full results are still under peer review, and additional data maturation may alter risk estimates or reveal new safety or efficacy signals.

Bottom line

BridgeBio Pharma's acoramidis demonstrates significant reductions in key clinical endpoints versus tafamidis and placebo in both real-world and Phase 3 trial settings, with robust statistical support for hospitalization and disease progression benefits. The safety profile is acceptable, with mild increases in certain adverse events but no excess discontinuation. Regulatory approvals across major markets are in place, supporting commercial potential. However, the relatively short follow-up and limited event counts for mortality and atrial fibrillation mean long-term benefits are not yet fully established. Observational study limitations and small subgroup sizes temper confidence in some analyses. Investors should watch for peer-reviewed publication of these results and longer-term data, especially regarding mortality and broader commercial uptake. The most important takeaway is that acoramidis is emerging as a differentiated therapy in ATTR-CM, but full long-term impact and market penetration remain to be seen.

Announcement summary

(NASDAQ:BBIO) BridgeBio Pharma, Inc. announced new real-world evidence and Phase 3 ATTRibute-CM sub-analyses of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. Acoramidis is described as the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. A retrospective analysis using the Epic COSMOS database included 910 acoramidis-treated and 1,774 tafamidis-treated individuals with ATTR-CM, matched for baseline characteristics. The composite endpoint of death, all-cause hospitalization, new-onset atrial fibrillation, or diuretic intensification was significantly lower with acoramidis: unadjusted HR 0.82 (95% CI 0.72-0.90; p<0.001), primary analysis 18% lower risk (HR 0.82; 95% CI 0.73-0.93; p<0.01), and sensitivity analysis HR 0.84 (95% CI 0.72-0.97; p=0.02). Acoramidis-treated individuals had a 27% lower risk of cardiovascular hospitalization (HR 0.73; 95% CI 0.62-0.86; p<0.001), a 27% lower risk of heart failure hospitalization (HR 0.73; 95% CI 0.62-0.87; p<0.001), and a 25% lower risk of all-cause hospitalization (HR 0.75; 95% CI 0.64-0.88; p<0.001) compared to tafamidis. Diuretic intensification was 17% lower with acoramidis (HR 0.83; 95% CI 0.71-0.95; p<0.01). Differences in death (HR 0.85; 95% CI 0.62-1.20; p=0.34) and new-onset atrial fibrillation (HR 0.88; 95% CI 0.68-1.13; p=0.31) numerically favored acoramidis but did not reach statistical significance. Kaplan-Meier curves showed early and sustained separation between treatment groups (p=0.0014). These findings replicate and expand on prior claims-based studies, including a 34% reduction in a composite of clinical worsening events with acoramidis versus tafamidis (p=0.046). In a post hoc analysis of ATTRibute-CM (N=611), survival at 30 months fell from 86.7% in participants with no cardiovascular-related hospitalizations (CVH) to 68.4% with one and 47.7% with two or more (log-rank p<0.0001). Acoramidis reduced the annualized frequency of CVH by 50% through Month 30 versus placebo (p<0.0001). In the ATTRibute-CM study, a greater Day 28 eGFR dip following acoramidis initiation was associated with a reduced risk of mortality or recurrent CVH, building upon a previously demonstrated 42% reduction in recurrent CVH/ACM with acoramidis over placebo. In p.Val142Ile variant patients (n=35), acoramidis attenuated 30-month declines in KCCQ-OS score by 23.3 points (p=0.005), EQ VAS score by 25.8 points (p=0.003), and EQ-5D-5L index score by 0.26 (p=0.018), and previously showed a 69% reduction in risk of all-cause mortality or first CVH through Month 30. Additional presentations included findings on the prognostic value of the sTTR to NT-proBNP ratio, increased falls and fractures in ATTR-CM, long-term effects of acoramidis on cardiac structure (ASCEND-ATTR), and outcomes in patients switching from tafamidis to acoramidis. Among women in ATTRibute-CM, acoramidis reduced the risk of cardiovascular mortality or first CVH through Month 30 and attenuated NT-proBNP rise versus placebo. Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby (acoramidis) versus placebo, with discontinuation rates due to adverse events of 9.3% and 8.5%, respectively. Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the EMA, Japanese PMDA, Swissmedic, UK MHRA, and Brazilian ANVISA, all specifying near-complete TTR stabilization.

Disagree with this article?